Cannabis in Cancer Care

Clinical Pharmacology and Therapeutics

Volumn 97, Issue 6, 2015, Pages 575-586

  Abrams, D I ^a   Guzman, M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABINOID 2 RECEPTOR; CANNABIS; DRONABINOL; NABILONE; NABIXIMOLS; OPIATE; MEDICAL CANNABIS; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ANTIEMETIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ARTICLE; BIOLOGICAL ACTIVITY; CANCER PAIN; CANCER RISK; CANCER THERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DEPRESSION; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG POTENTIATION; DRUG SAFETY; EUPHORIA; HUMAN; MOTOR DYSFUNCTION; NEUROPATHY; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; WASTING SYNDROME; ANIMAL; APPETITE; DRUG EFFECTS; DRUG INTERACTION; NEOPLASMS; PAIN, INTRACTABLE; PATHOPHYSIOLOGY; VOMITING;

ANALGESIA; ANALGESICS, OPIOID; ANIMALS; APPETITE; CANNABINOIDS; DRUG INTERACTIONS; HUMANS; MEDICAL MARIJUANA; NEOPLASMS; PAIN, INTRACTABLE; VOMITING;

EID: 84938523805     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.108     Document Type: Article

References (71)

1. Pertwee, R.G. (ed). Handbook of Cannabis (Oxford University Press, Oxford, UK, 2014).
2. Sallen, S.E., Zinberg, N.E. & Frei, E. Antiemetic effect of delta-9-THC in patients receiving cancer chemotherapy. N. Engl. J. Med. 293, 795-797 (1975).
3. Gorter, R., Seefried, M. & Volberding, P. Dronabinol effects on weight in patients with HIV infection. AIDS. 6, 127 (1992).
4. Beal, J.E. et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J. Pain Symptom Manage. 10, 89-97 (1995).
5. Russo, E.B. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br. J. Pharmacol. 163, 1344-1364 (2011).
6. Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol. 156, 397-411 (2009).
7. Miller, L.K. & Devi, L.A. The highs and lows of cannabinoid receptor expression in disease: Mechanisms and their therapeutic implications. Pharmacol. Rev. 63, 461-470 (2011).
8. Borgelt, L.M., Franson, K.L., Nussbaum, A.M. & Wang, G.S. The pharmacologoic and clinical effects of medical cannabis. Pharamcotherapy. 3, 195-209 (2013).
9. Joy, J.E., Watson, S.J. & Benson, J.A. (eds). Marijuana and Medicine: Assessing the Science Base (National Academy Press, Washington, DC, 1999).
10. Karschner, E.L. et al. Plasma cannabinoid pharmacokinetics following controlled oral Delta-9tetrahydrocannabinol and oromucosal cannabis extract administration. Clin. Chem. 57, 66-75 (2011).
11. Engels, F.K. et al. Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel. Oncologist. 12, 291-300 (2007).
12. Sutton, I.R. & Daeninck, P. Cannabinoids in the management of intractable chemotherapy-induced nausea and vomiting and cancerrelated pain. J. Support. Oncol. 4, 531-535 (2006).
13. Tramer, M.R. et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: Quantitative systematic review. BMJ. 323, 16-21 (2001).
14. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. J. Ethnopharmacol. 105, 1-25 (2006).
15. Walsh, D., Nelson, K.A. & Mahmoud, F.A. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 11, 137-143 (2003).
16. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting. Br. J. Clin. Pharmacol. 70, 656-663 (2010).
17. Brisbois, T.D. et al. Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: Results of a randomized, double-blind, placebo-controlled pilot trial. Ann. Oncol. 22, 2086-2093 (2011).
18. Mechoulam, R., Berry, E.M., Avraham, Y., DiMarzo, V. & Fride, E. Endocannabinoids, feeding and suckling-from our perspective. Int. J. Obes. (Lond). Suppl.1, S24-S28 (2006).
19. Christensen, R., Kristensen, P.K., Bartals, E.M., Bliddal, H. & Astrup, A. Efficacy and safety of the weight-loss drug rimonabant: A metaanalysis of randomised trials. Lancet. 370, 1706-1713 (2007).
20. Le Strat, Y. & Le Foll, B. Obesity and cannabis use: Results from 2 representative national surveys. Am. J. Epidemiol. 174, 929-933 (2011).
21. Penner, E.A., Buettner, H. & Mittleman, M.A. The impact of marijuana use on glucose, insulin, and insulin resistance. Am. J. Med. 126, 583-589 (2013).
22. Fine, P.G. & Rosenfeld, M.J. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Med. J. 4, eooXX (2013).
23. Facci, L. et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. U. S. A. 92, 3376-3380 (1995).
24. Ibrahim, M.M. et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc. Natl. Acad. Sci. U. S. A. 102, 3093-3098 (2005).
25. Elikottil, J., Gupta, P. & Gupta, K. The analgesic potential of cannabinoids. J Opioid Manage. 5, 341-357 (2009).
26. Noyes, R., Brunk, S., Baram, D. & Canter, A. Analgesic effect of delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. 15, 139-143 (1975).
27. Noyes, R., Brunk, S., Avery, D. & Canter, A. The analgesic properties of delta-9-tertrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18, 84-89 (1975).
28. Noyes, R. & Baram, D. Cannabis analgesia. Compr. Psychiatry. 15, 531 (1974).
29. Johnson, J.R. et al. Multicenter, double-blind, randomized, placebocontrolled, parallel-group study of the efficacy, safety and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom. Manage. 39, 167-178 (2010).
30. Herzberg, U., Eliav, E., Bennett, G.J. & Kopin, I.J. The analgesic effect of R(1)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci. Lett. 221, 157-160 (1997).
31. Abrams, D.I. et al. Cannabis in painful HIV-associated sensory neuropathy: A randomized, placebo-controlled trial. Neurology. 68, 515-521 (2007).
32. Wilsey, B. et al. A randomized, placebo-controlled crossover trial of cannabis cigarettes in neuropathic pain. J. Pain. 9, 506-521 (2008).
33. Ellis, R.J. et al. Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychoparmacology. 34, 672-680 (2009).
34. Wilsey, B. et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J. Pain. 14, 136-148 (2013).
35. Svendsen, K.B., Jensen, T.S. & Back, FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 329, 253-260 (2004).
36. Rog, D.J., Nurmikko, T.J., Fride, T. & Young, C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 65, 812-819 (2005).
37. Lynch, M.E., Cesar-Rittenberg, P. & Hohmann, A.G. A double-blind, placebo-controlled, cross-over pilot with extension using an oral mucosal cannabinoid-extract for treatment of chemotherapyinduced neuropathic pain. J. Pain Symptom. Manage. 47, 166-173 (2014).
38. Ward, S.J., McAllister, S.D., Neelakantan, H. & Walker, E.A. Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy. Br. J. Pharmacol. 171, 636-645 (2014).
39. Cichewicz, D.L. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 74, 1317-1324 (2004).
40. Abrams, D.I. et al. Cannabinoid:opioid interaction in chronic pain. Clin. Pharmacol. Ther. 90, 844-851 (2011).
41. Russo, E.B., Guy, G.W. & Robson, P.J. Cannabis, pain, and sleep: Lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem. Biodivers. 4, 1729-1743 (2007).
42. Ware, M.A. et al. Smoked cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ. 182, E694-701 (2010).
43. Bar-Sela, G. et al. The medical necessity for medicinal cannabis: Prospective, observational study evaluating treatment in cancer patients on supportive or palliative care. Evid. Based Complement. Altern. Med. 2013, 510392 (2013).
44. Guzman M. Cannabinoids: Potential anticancer agents. Nat. Rev. Cancer. 3, 745-755 (2003).
45. Velasco, G., Sánchez, C. & Guzmán, M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer. 12, 436-444 (2012).
46. Bowles, D.W., O'Bryant, C.L., Camidge, R. & Jimeno, A. The intersection between cannabis and cancer in the United States. Crit. Rev. Oncol. Hematol. 83, 1-10 (2012).
47. Munson, A.E., Harris, L.S., Friedman, M.A., Dewey, W.L. & Carchman, R.D. Antineoplastic activity of cannabinoids. JNCI. 55, 597-602 (1975).
48. Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: Pros and cons of an antitumour strategy. Br. J. Pharmacol. 148, 123-135 (2006).
49. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 95, 8375-8380 (1998).
50. McKallip, R.J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. Blood. 100, 627-634 (2002).
51. Patsos, H.A., Hicks, D.J., Greenhough, A., Williams, A.C. & Paraskeva, C. Cannabinoids and cancer: Potential for colorectal cancer therapy. Biochem. Soc. Trans. 33, 712-714 (2005).
52. Sarfaraz, S., Afaq, F., Adhami, V.M. & Mukhtar, H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 65, 1635-1641 (2005).
53. McAllister, S.D. et al. Cannabinoids selectively inhibit proliferation and induce death of cultured glioblastoma multiforme cells. J. Neurooncol. 74, 31-40 (2005).
54. Torres, S. et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther. 10, 90-103 (2011).
55. Marcu, J.P. et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther. 9, 180-189 (2010).
56. Guzman, M. et al. A pilot study of Delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer. 95, 1-7 (2006).
57. U.S. Department of Health and Human Services NTP Technical Report on the Toxicology and Carcinogenesis Studies of 1-Trans-Delta9-Tetrahydrocannabinol in F344/N Rats and B6C3F1 Mice (Gavage Studies). TR-446, November 1996. http://ntp.niehs.nih. gov/ntp/htdocs/LT-rpts/tr446.pdf
58. Callaghan, R.C., Allebeck, P. & Sidorchuk, A. Marijuana use and risk of lung cancer: A 40-year cohort study. Cancer Causes Control. 24, 1811-1820 (2013).
59. Sidney, S., Quesenberry, C.P., Friedman, G.D. & Tekewa, I.S. Marijuana use and cancer incidence (California, USA). Cancer Causes Control. 8, 722-728 (1997).
60. Hashibe, M. et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based casecontrol study. Epidemiol. Biomarkers Prev. 15, 1829-1834 (2006).
61. Mehra, R., Moore, B.A., Crothers, K., Tetrault, J. & Fiellin, D.A. The association between marijuana smoking and lung cancer: A systematic review. Arch. Intern. Med. 166, 1359-1367 (2006).
62. Zhang, L.R. et al. Cannabis smoking and lung cancer risk: Pooled analysis in ther International Lung Cancer Consortium. Int. J. Cancer. 136, 894-903 (2015).
63. Daling, J.R. et al. Association of marijuana use and the incidence of testicular germ cell tumors. Cancer. 115, 1215-1223 (2009).
64. Trabert, B. et al. Marijuana use and testicular germ cell tumors. Cancer. 117, 848-853 (2011).
65. Lacson, J.C. et al. Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer. 118, 5374-5383 (2012).
66. Thomas, A.A. et al. Association between cannabis use and the risk of bladder cancer: Results from the California Men's Health Study. Urology. 85, 388-393 (2015).
67. Huang, Y.H. et al. An epidemiologic review of marijuana and cancer: An update. Cancer Epidemiol. Biomarkers Prev. 24, 15-31 (2015).
68. Volkow, N.D., Baler, R.D., Compton, W.M. & Weiss, S.R.B. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219-2227 (2014).
69. Carter, G.T., Weydt, P., Kyashna-Tocha, M. & Abrams, D.I. Medicinal cannabis: Rational guidelines for dosing. IDrugs. 7, 464-470 (2004).
70. Bostwick, J.M., Reisfield, G.M. & DuPont, R.L. Medicinal use of marijuana. N. Engl. J. Med. 368, 866-868 (2013).
71. Adler, J.N. & Colbert, J.A. Medicinal use of marijuana-polling results. N. Engl. J. Med. 368, e30 (2013).